Jonathan Slonin's most recent trade in Pacira BioSciences Inc was a trade of 5,084 Common Stock done at an average price of $26.4 . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.40 per share. | 03 Jun 2025 | 5,084 | 181,959 (0%) | 0% | 26.4 | 134,218 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 93,600 | 187,043 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.40 per share. | 02 Jan 2025 | 879 | 93,443 (0%) | 0% | 18.4 | 16,174 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.33 per share. | 02 Jan 2025 | 371 | 94,322 (0%) | 0% | 18.3 | 6,800 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.05 per share. | 01 Aug 2024 | 945 | 94,306 (0%) | 0% | 20.0 | 18,947 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 01 Aug 2024 | 305 | 95,251 (0%) | 0% | 20.8 | 6,329 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.25 per share. | 28 Jun 2024 | 2,836 | 95,556 (0%) | 0% | 28.3 | 80,117 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.46 per share. | 28 Jun 2024 | 914 | 98,392 (0%) | 0% | 28.5 | 26,012 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 24.33 per share. | 28 Jun 2024 | 437 | 99,306 (0%) | 0% | 24.3 | 10,634 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 54,300 | 98,869 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.57 per share. | 11 Jun 2024 | 5,012 | 44,569 (0%) | 0% | 28.6 | 143,193 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.89 per share. | 03 Jun 2024 | 1,615 | 49,581 (0%) | 0% | 30.9 | 49,887 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 5,000 | 51,196 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Sale of securities on an exchange or to another person at price $ 37.87 per share. | 06 Jun 2023 | 490 | 36,323 (0%) | 0% | 37.9 | 18,554 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Sale of securities on an exchange or to another person at price $ 38.99 per share. | 06 Jun 2023 | 471 | 36,813 (0%) | 0% | 39.0 | 18,365 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Sale of securities on an exchange or to another person at price $ 55.70 per share. | 03 Aug 2022 | 308 | 37,079 (0%) | 0% | 55.7 | 17,156 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Sale of securities on an exchange or to another person at price $ 57.19 per share. | 05 Jul 2022 | 924 | 37,387 (0%) | 0% | 57.2 | 52,842 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 06 Jun 2022 | 24,800 | 24,800 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2022 | 9,900 | 38,097 (0%) | 0% | 0 | Common Stock | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Sale of securities on an exchange or to another person at price $ 61.37 per share. | 06 Jun 2022 | 362 | 28,197 (0%) | 0% | 61.4 | 22,217 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.37 per share. | 23 May 2022 | 2,000 | 28,559 (0%) | 0% | 52.4 | 104,740 | Common Stock |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2022 | 2,000 | 35,500 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Pacira BioSciences Inc | Jonathan Slonin | Chief Clinical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2021 | 5,000 | 26,350 (0%) | 0% | 0 | Common Stock |